Company profile
Amyl Therapeutics company profile
Amyl Therapeutics is a preclinical stage biotechnology company. Amyl Therapeutics uses a novel mechanism to bind to the amyloid fold of toxic protein aggregates of various types, including antibody light chain (AL) or transthyretin (TTR) aggregates, which accumulate in peripheral organs to cause systemic amyloidosis diseases, but also amyloid-β (Aβ), Tau, and α-synuclein aggregates, which accumulate in the brain to cause Alzheimer's and Parkinson's diseases.
Business identity
- Website
- https://www.amyltx.com
- Operating status
- Active
- Company type
- For Profit
- Employee range
- 1-10 employees
- Revenue range
- $10M-$100M
- Founded
- 2020-11-01, Month
Headquarters
- Headquarters
- Ligny, Wallonia, Belgium
- Postal code
- 4301
- Country code
- BE
- Continent
- Europe